Business Context and Reporting Period
This Form 8-K is a current report filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on August 23, 2021. The registrant is a Delaware corporation and an emerging growth company. The filing primarily addresses unregistered sales of equity securities and other events related to compensation for the Chairman of the Clinical Advisory Committee.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data disclosed relates to a compensation transaction:
- Total Bonus Obligation (Bonus 2): 434,673 GBP (approximately $596,545).
- Current Transaction Value: 134,748.63 GBP (approximately $184,605.62).
- Shares Issued: 61,535 shares of common stock.
- Valuation Price: $3.00 per share.
Material Changes
The material change reported is the issuance of 61,535 shares of common stock to Prof. Jagdeep Nanchahal. This issuance satisfies the remaining 31% of a performance-based bonus ("Bonus 2") earned upon the Company raising a minimum of $15 million in additional funding after December 1, 2020. The funding condition was met on August 23, 2021. Previous portions of this bonus (50% and 19%) were satisfied by share issuances in March and April 2021.
Guidance, Outlook, and Risks
Management Commentary: The issuance was made at the request of Prof. Nanchahal under the Company's 2020 Omnibus Incentive Plan. The shares were issued at $3.00 per share, which was the lower of the fixed price or the market price on the grant date.
Risks and Contingencies: The securities were issued pursuant to an exemption from registration under Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act. The shares are subject to transfer restrictions and contain legends stating they have not been registered and may not be sold absent registration or an exemption.
Investor Verification Checklist
- Verify the total number of shares outstanding post-issuance to assess dilution impact.
- Confirm the status of the $15 million funding raise mentioned as the trigger for the bonus.
- Review the 2020 Omnibus Incentive Plan to ensure the issuance was within authorized limits.
- Check for any subsequent filings regarding the remaining cash portion of the bonus (if applicable) or further equity issuances.